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Nine years after its founding, Retrovirology has moved to the forefront of virology journals in Impact Factor.In 2004, during the early days of Open Access, I had the
opportunity to start Retrovirology employing the then
“new way” of publishing [1]. Retrovirology was not the
first journal that I helped found. Ten years earlier, in
1994, I was one of nine editors, led by Dr. Chuan C.
Chang, who started the Journal of Biomedical Science
[2]. The Journal of Biomedical Science originated as a
subscription-based journal; thus, when Retrovirology
began I understood the difference between a publishing
model based on subscription (readers/subscribing librar-
ies and institutions pay) versus Open Access (authors
pay, and all articles are freely accessible by readers).
At the outset, there were two challenges to Retrovirol-
ogy’s success. The first was whether Open Access would
be a sustainable business model. In those days, this was
an unknown. Today, the increasing popularity of jour-
nals like PLoS ONE, Nature’s Scientific Reports (www.na-
ture.com/srep/index.html), Cell Reports (www.cellreports.
cell.com), Cell and Bioscience [3], Journal of the Inter-
national AIDS Society (www.jiasociety.org/index.php/
jias), and the recent migration of journals such as
EMBO Molecular Medicine from a subscription to an
Open Access format indicate that the latter business
model has achieved financial traction, if not overt
profitability.
The second challenge was an early notion held by
some that Open Access journals would publish lower
“quality” science with inherently less “visible” findings. A
few contentious colleagues even insisted, “Retrovirology
will never reach the Impact Factors of the Journal of Vir-
ology, Virology, and the Journal of General Virology!” In
retrospect, they were wrong; Retrovirology achieved and
surpassed those metrics. Indeed, in the 2011 tabulation
of Impact Factor and Immediacy Index, Retrovirology
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reproduction in any medium, provided the orJAIDS, J Virol., Virology, J Gen Virology; and two estab-
lished standards of molecular biology and biochemistry,
the Journal of Molecular Biology and the Journal of Bio-
logical Chemistry (Figure 1). Of interest, amongst these
journals, Retrovirology is the only Open Access journal.
This means that only in Retrovirology are your papers
immediately available for all to read, the very day that
they are published, in full text form without the readers
being encumbered by subscription fees. This Open Ac-
cess feature may explain the large advantage in Immedi-
acy Index for papers published in Retrovirology over the
next-ranked journal, the Journal of Infectious Diseases
(Figure 1).
Impact Factor and Immediacy Index are two of several
proxies of a journal’s quality, and one should interpret
cautiously their meaning [4]. Arguably, a better measure
is to ask how a journal’s papers have made a difference
in its field. In this respect, a significant example can
be drawn from six Retrovirology papers published in
December 2010 that were the first to pivotally correct
the then held belief that XMRV was an etiological cause
of Chronic Fatigue Syndrome (CFS) [5-10]. In that in-
stance, Retrovirology’s Open Access format was particu-
larly instrumental in permitting interested individuals,
who were not career scientists, to freely, rapidly, and
fully access those paradigm-changing peer-reviewed
publications.
Increasing data support the absence of inherent rea-
sons for qualitative difference between papers published
in subscription versus Open Access journals [11]. In my
view, whether a journal moves to the fore is dictated by
the diligence and dedication of its editorial board. Retro-
virology’s strong progress forward is owed to the efforts
of its board members (http://www.retrovirology.com/
about/edboard).
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Figure 1 Impact factor and immediacy index of Retrovirology and the indicated journals. The data are from the 2011 Journal Citation
Reports (ISI Web of Knowledge, Thomson-Reuters).
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